15. Inclusion body myositis Clinical trials / Disease details
Clinical trials : 42 / Drugs : 60 - (DrugBank : 16) / Drug target genes : 12 - Drug target pathways : 123
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2007-004359-12-IT (EUCTR) | 05/04/2007 | 21/11/2007 | Simvastatin treatment in inclusion body myositis (IBM) - ND | Simvastatin treatment in inclusion body myositis (IBM) - ND | INCLUSION BODY MYOSITIS MedDRA version: 6.1;Level: PT;Classification code 10028289 | Trade Name: SIVASTIN INN or Proposed INN: Simvastatin INN or Proposed INN: Immunoglobulins, normal human, for intravascular adm. | ISTITUTO NEUROLOGICO CARLO BESTA | NULL | Not Recruiting | Female: yes Male: yes | Italy | ||||
| 2 | EUCTR2006-005942-35-IT (EUCTR) | 14/03/2007 | 04/06/2007 | Simvastatin therapy in IBM - ND | Simvastatin therapy in IBM - ND | inclusion body myositis MedDRA version: 6.1;Level: PT;Classification code 10028641 | Trade Name: SIVASTIN INN or Proposed INN: Simvastatin Trade Name: FLEBOGAMMA 5% INN or Proposed INN: Immunoglobulins, normal human, for intravascular adm. | POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI | NULL | Not Recruiting | Female: yes Male: yes | Italy |